klaus wolff

Research

Scientific Accomplishments (in Cooperation with Associates at the Department of Dermatology, University of Innsbruck and Vienna):
  1. Cell Biology:
    • Delineation of the lysosomal system of the epidermis (1968-1974)
    • Studies on the intercellular compartment of the epidermis (glycokalyx, permeability) (1968-1975)
    • Pigment transfer: distribution pattern of melanosome depends on size of particles (1971-1973)
    • Langerhans cells: Langerhans cells have ATPase (1963), Langerhans cells are not related to melanocytes (1966-1969), Langerhans cells are mesenchymal cells (1972), Langerhans cells bear immunological receptors (Fc,C3, Ia antigens) (1977)
    • Langerhans cells fulfill a critical accessory function in the generation of CTCL (1982)
    • UV effects on Langerhans cells: abrogation of allogeneic and syngeneic T cell activating and antigen presenting functions of Langerhans cells by UV (1980-1982)
    • discovery and characterisation of the dendritic Thy-1+ epidermal cell system (1983)
    • Langerhans cells are infected by and represent reservoir for HIV (1987, 1988)
    • Cadherins in Angioneogenesis (1996)
    • Discovery of the endogenous retrovirus MERV I in melanoma (2003)

  2. Immunodermatology:
    • Demonstration of ultrastructural localization of autoantibodies and immune complexes in the skin in pemphigus, dermatitis herpetiformis, herpes gestationis, CDLE, SLE (1971-1976)
    • Complement activation on intermediate sized filaments in skin cells (1982)
    • Immunophenotyping in GvH (1987)
    • Immunophenotyping of Histiocytosis X (1988)
    • Class II alloantigen expression in epidermis (1987)
    • Concept of the skin as an immune organ (1985-1992 )
    • Lymphocyte homing to skin (SCID mouse model) (1996)
    • Autoantibodies in erythema multiforme (1995)
    • FgRII in immune complex vasculitis (1996)

  3. Experimental Dermatology:
    • Elaboration of mouse model for erythropoietic protoporphyria (1975, 1976)
    • First experimental production of staphylococcal scalded skin syndrome in adult humans (1974)

  4. Clinical Research:
    • Melanoderma in malignant melanoma (1976)
    • C4 Deficiency and LE (1982)
    • IF mapping of antigenic determinants in mechanobullous diseases (1981)
    • Generalized atrophic benign epidermolysis bullosa (1982)
    • Epiluminescence microscopy for early detection of melanoma (1987)
    • Vegetating cicatricial pemphigoid (1987)
    • Digitalized epiluminescence microscopy (1995)

  5. Therapy:
    • First successful treatment of pemphigus with azathioprine (1969)
    • Photochemotherapy in psoriasis and other diseases, clinical effectiveness and mechanism (PUVA) (1975-1985)
    • Retinoid-PUVA-chemophotochemotherapy (1978)
    • Topical immunomodulation in the treatment of skin disease 1994/95
    • Topical immunosuppression by macrolides (1996)
    • BCL-2 antisense therapy for melanoma (1998)
    • Interferon-alpha 2a as adjuvant therapy in melanoma (1998)
    • Ras antagonists for melanoma therapy (1999)
    • First pharmacogenomic study in humans (psoriasis, pimecrolimus) (2002)
    • Systemic, skin targeted immunomodulation (Pimecrolimus) (2002)
    • Protectoin of myocardium from ischemia reperfusion injury by peptide Bb15-42, 2005.